Clinical Trial Update: Panitumumab and Gemcitabine in Relapsed Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of panitumumab and gemcitabine in relapsed ovarian, fallopian tube, and primary peritoneal cancers was terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Panitumumab (panitumumab)

Snippet

Sponsor: Women and Infants Hospital of Rhode Island | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-08-25